



## Harvard Bioscience, Inc. Schedules First Quarter 2009 Conference Call for April 30, 2009

HOLLISTON, Mass.--(BUSINESS WIRE)--Apr. 16, 2009-- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce results for the first quarter ended March 31, 2009 after market trading hours on Thursday, April 30, 2009.

A conference call to discuss first quarter ended March 31, 2009 financial results will be held on Thursday, April 30, 2009 at 5:30 p.m. Boston time. In addition, management may answer questions concerning business and financial developments and trends, the Company's view on earnings forecasts, and other business and financial matters affecting the Company. Some of the information to be presented on the call or provided in response to questions may contain information that has not previously been disclosed.

The conference call will be simultaneously broadcast over the Internet and can be accessed through the Harvard Bioscience, Inc. website. To listen to the conference call, log on to our website at [www.harvardbioscience.com](http://www.harvardbioscience.com) and click on the Earnings Call icon. Financial and other statistical information presented on the call, including our earnings release, will also be available on the investor relations section of our website. Click on the investor relations button and then click on the press release or webcast icon, as appropriate. If you are unable to listen to the live webcast, the call will be archived in the investor relations section of our website. The live conference call is also accessible by dialing 866-783-2141 and referencing the pass code of "78640960". A replay of this conference call will be available from 8:30 p.m. on April 30, 2009 through May 7, 2009 and will be accessible by dialing 888-286-8010 and referencing the pass code of "85099630".

### About Harvard Bioscience

Harvard Bioscience is a global developer, distributor, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 900 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Thermo Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain with additional facilities in France and Canada. For more information, please visit [www.harvardbioscience.com](http://www.harvardbioscience.com).

*The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, those factors set forth under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.*

Source: Harvard Bioscience, Inc.

Harvard Bioscience, Inc.  
David Green, 508-893-8999  
President

[dgreen@harvardbioscience.com](mailto:dgreen@harvardbioscience.com)

Fax: 508-429-8478

or

Chane Graziano  
CEO

[cgraziano@harvardbioscience.com](mailto:cgraziano@harvardbioscience.com)

or

Tom McNaughton  
CFO

[tmcnaughton@harvardbioscience.com](mailto:tmcnaughton@harvardbioscience.com)

Disclaimer:

The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrences or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience's web site. For Harvard Bioscience's most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at <http://www.sec.gov>.